Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY).

Danielle Carroll,Rob McEwen,Iwanka Kozarewa,Elizabeth A. Harrington,Anne L’Hernault,Jayantha Ratnayake,Richard Mather,Darren Hodgson,J. Carl Barrett,Jan G. C. E. Cosaert,Pierre-Emmanuel Brachet,Petros Grivas,Simon Chowdhury,Thomas Powles,Donal Landers

Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY).

2019

Danielle Carroll
Rob McEwen
Iwanka Kozarewa
Elizabeth A. Harrington
Anne L’Hernault
Jayantha Ratnayake
Richard Mather
Darren Hodgson
J. Carl Barrett
Jan G. C. E. Cosaert
Pierre-Emmanuel Brachet
Petros Grivas
Simon Chowdhury
Thomas Powles
Donal Landers

4553Background: BISCAY is a biomarker-directed Ph1b multi-arm platform study exploring the combination of targeted therapies with anti-PD-L1, Durvalumab, in advanced urothelial cancer. Methods: Nex...

Keywords:

Metastatic bladder cancer
Circulating tumor DNA
Cancer research
Biomarker (medicine)
Pathology
Medicine
urothelial cancer
genomic profiling
Durvalumab
clinical efficacy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations